Terms: = Prostate cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
53 results:
1. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
2. erbb3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive prostate cancer and is Associated with a Unique AR Activity Signature.
Vellky JE; Kirkpatrick BJ; Gutgesell LC; Morales M; Brown RM; Wu Y; Maienschein-Cline M; Notardonato LD; Weinfeld MS; Nguyen RH; Brister E; Sverdlov M; Liu L; Xu Z; Kregel S; Nonn L; Vander Griend DJ; Reizine NM
Clin Cancer Res; 2024 Apr; 30(8):1530-1543. PubMed ID: 38306015
[TBL] [Abstract] [Full Text] [Related]
3. Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.
Fletcher KA; Alkurashi MH; Lindsay AJ
Invest New Drugs; 2024 Feb; 42(1):14-23. PubMed ID: 37957513
[TBL] [Abstract] [Full Text] [Related]
4. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the her3/erbb3 receptor tyrosine kinase.
Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
[TBL] [Abstract] [Full Text] [Related]
5. Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer.
Li J; Wu H; Lv S; Quan D; Yang D; Xu J; Chen B; Ou B; Wu S; Wei Q
Pharmazie; 2022 Feb; 77(2):59-66. PubMed ID: 35209965
[No Abstract] [Full Text] [Related]
6. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type prostate cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract] [Full Text] [Related]
7. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
8. Anti‑her3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
9. Glioma pathogenesis-related protein 1 performs dual functions in tumor cells.
Wang J; Li Z; Yin F; Zhang R; Zhang Y; Wang Z; Sheng X
Cancer Gene Ther; 2022 Mar; 29(3-4):253-263. PubMed ID: 33742130
[TBL] [Abstract] [Full Text] [Related]
10. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract] [Full Text] [Related]
11. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
12. The role of ErbB4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
13. Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant prostate cancer.
Benelli R; Barboro P; Costa D; Astigiano S; Barbieri O; Capaia M; Poggi A; Ferrari N
Int J Mol Sci; 2019 Dec; 20(23):. PubMed ID: 31816863
[TBL] [Abstract] [Full Text] [Related]
14. treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan.
Shah R; Botteman M; Waldeck R
Future Oncol; 2019 Dec; 15(35):4069-4081. PubMed ID: 31687847
[No Abstract] [Full Text] [Related]
15. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.
Jathal MK; Steele TM; Siddiqui S; Mooso BA; D'Abronzo LS; Drake CM; Whang YE; Ghosh PM
Br J Cancer; 2019 Jul; 121(3):237-248. PubMed ID: 31209328
[TBL] [Abstract] [Full Text] [Related]
16. Response to erbb3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
17. Small-Molecule Activators of Protein Phosphatase 2A for the treatment of Castration-Resistant prostate cancer.
McClinch K; Avelar RA; Callejas D; Izadmehr S; Wiredja D; Perl A; Sangodkar J; Kastrinsky DB; Schlatzer D; Cooper M; Kiselar J; Stachnik A; Yao S; Hoon D; McQuaid D; Zaware N; Gong Y; Brautigan DL; Plymate SR; Sprenger CCT; Oh WK; Levine AC; Kirschenbaum A; Sfakianos JP; Sears R; DiFeo A; Ioannou Y; Ohlmeyer M; Narla G; Galsky MD
Cancer Res; 2018 Apr; 78(8):2065-2080. PubMed ID: 29358171
[TBL] [Abstract] [Full Text] [Related]
18. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast cancer.
Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
[TBL] [Abstract] [Full Text] [Related]
19. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Lu S; Dong Z
Int J Oncol; 2017 Jun; 50(6):2113-2122. PubMed ID: 28440478
[TBL] [Abstract] [Full Text] [Related]
20. [A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor].
Ni J; Yin ZM; Yuan SH; Liu NF; Li L; Xu XX; Lou HM
Zhonghua Fu Chan Ke Za Zhi; 2017 Mar; 52(3):168-174. PubMed ID: 28355688
[No Abstract] [Full Text] [Related]
[Next]
